{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045952","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.209708+00:00","generated_at":"2026-05-30T03:22:33.383696+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InfuSystem reports record Q3 revenue of $35.3M, up 11% YoY; net income +162%","bullets":["Net revenue $35.3M (+11% YoY); Patient Services $20.8M (+8%), Device Solutions $14.5M (+15%).","Net income $1.8M (+162%), diluted EPS $0.08; Adj EBITDA $7.9M (+27%), margin 22.3%.","Operating cash flow YTD $12.5M (+91%); liquidity $46.9M as of Sept 30, 2024.","Reaffirms FY2024 guidance: high-single-digit revenue growth, Adj EBITDA margin high-teens.","New partnerships: Smith+Nephew for NPWT and exclusive Chemo Mouthpiece deal with Sanara MedTech."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045952","json":"https://secwatch.observer/filing/0001628280-24-045952.json","markdown":"https://secwatch.observer/filing/0001628280-24-045952.md","text":"https://secwatch.observer/filing/0001628280-24-045952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024045952/0001628280-24-045952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024045952/infu-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:22:33.383696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}